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(SDS) with linezolid. The aim of the study was to estimate the budget impact of 
SDS vs conventional strategy (CS, only intravenous) with linezolid in Mexico, from 
the perspective of Instituto Mexicano del Seguro Social (IMSS). Methods: Budget 
impact analysis (BIA) considered direct medical costs of linezolid (intravenous 
and tablets), length of stay, physician visits, route of administration, laboratory 
and imaging tests, as well as outpatient control (unit costs extracted from IMSS 
sources). Costs are expressed in 2013 US$ (1US$:€ 0.719). The resource use profile 
was estimated by Delphi method in a panel of 10 experienced infectologists. A 
BIA considering two scenarios was performed: i) budget impact of use CS in 100% 
of cases of nosocomial pneumonia caused by GPB (15,135) and ii) budget impact 
of use of SDS only in candidates (7,718 cases), based on the National budget allo-
cated to health in 2013. Results: The per-patient average treatment cost (ATC) 
of SDS was $10,116 ($9,345-10,887) whereas the per-patient ATC of CS was $17,251 
($16,379-18,124). The scenario i) represents 2.79% of National budget allocated to 
health, whereas scenario ii) represents 2.19%. This means potential savings of 0.6% 
of National budget allocated to health ($55,078,697). With these resources, CS treat-
ment could be provided to 3,192 additional nosocomial pneumonia patients caused 
by GPB in Mexico. ConClusions: In the Mexican setting, SDS with linezolid in 
suitable patients is an intervention that could promote significant savings regarding 
the use of only intravenous form of the drug, which represents an opportunity to 
allocate scarce resources in a more efficient way.
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objeCtives: The costs to the German hospitals of intensive care (ICU) patients 
and of surgical patients not admitted to the ICU were estimated in a previous cost-
effectiveness analysis of omega-3 FA-supplemented compared to standard PN regi-
mens. The supplementation with Omega-3 FA results in shorter LOS and reduced 
infection rate, with cost savings for 3,277 € per ICU patient and 1,515 € per not-ICU 
patients. We aimed to estimate the economic consequences of increasing the rate 
of omega-3 fatty acids (FA) supplemented parenteral nutrition (PN) regimens in 
German hospitals Methods: IMS-data recorded about 3 million lipid-containing 
PN days for Germany; the total number of patients in ICU or in ward receiving PN 
with lipids was estimated on average PN duration from the cost-effectiveness analy-
sis The costs related to the current use of omega-3 FA (about 29% of total lipid PN 
days) were compared with those expected with increasing percentages of omega-3 
FA-containing PN rates. Results: The yearly cost of the patient population (104,022 
ICU patients and 427,986 not-ICU patients) treated with current PN regimens mix 
amounts to about 6 billion Euro. The increase of omega-3 FA-containing PN propor-
tion up to 50% results in a saving of about 210 million Euro (2.7%); the exclusive 
use of omega-3 FA-containing PN regimes results in savings of 704 million Euro 
(11.6%). Encouraging omega-3 FA supplemented PN regimens is expected to save 
costs, because the use is associated with a reduction in hospital LOS (~ 850,000 days 
saved in the best scenario) and the number of nosocomial infections (~ 40,000 infec-
tions avoided in the best scenario). ConClusions: The potential of PN including 
omega-3 FAs in contributing to an improved quality of care/patient recovery and 
significant cost savings is not fully exploited in German hospitals.
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objeCtives: A new dry-powder inhaler combination for the treatment of asthma 
has appeared. The objective of the present study is to analyze the cost impact of the 
introduction of the new dry-powder inhaler (DPI) –beclomethasone dipropionate with 
formoterol combination (BEC/FOR) - in the treatment of the moderate to severe persis-
tent asthma Methods: A mathematical model was designed to estimate the finan-
cial impact of the partial substitution of DPI budesonide with formoterol (BUD/FOR) 
and DPI fluticasone propionate with salmeterol (FLU/SAL). Only direct health care 
costs were considered because the perspective of Spanish National Health Service 
(NHS) was adopted. The time horizon was four years Results: The prevalence is 
4.6% and it increases 0.26% yearly. Current annual total cost of treatment with BUD/
FOR and FLU/SAL is estimated in around 512; 538; 565 and 591 million € for 2013-2017 
respectively. The new total cost is estimated in about 511; 537; 562 and 587 million € 
with the introduction of BEC/FOR. The major determinants of costs were the exac-
erbations of asthma (44.5% of total cost), and the antiasthmatic drugs (40.2%). The 
pharmacological cost of BEC/FOR represented the 37.02% of the total of this option 
while those of FLU/SAL and BUD/FOR were the 39.75% and 41.27%, respectively. Finally, 
the introduction of BEC/FOR (share of 2; 4; 9 and 14% for 2013-2017) was associated 
with a roughly saving of 0.7; 1.2; 2.8 and 4.5 million € in the same time ConClusions: 
The utilization of beclomethasone dipropionate and formoterol in substitution of 
fluticasone and salmeterol, and budesonide and salmeterol, all of them as dry-powder 
inhaled, results in important savings of costs for the NHS
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objeCtives: The lack of treatment adherence and persistence is associated with 
poor clinical outcomes and higher costs. The aim of this study is to estimate 
the variation on COPD costs that may take place as a consequence of improving 
spite of high heterogeneity found in NI reports (which may decrease the quality of 
the information recorded), the local data reported in this study can help clinicians in 
the choice of first line antibiotics in order diminish the probability of unsuccessful 
treatment and additionally to reduce the emergence of resistant organisms, which 
could cause negative economic impact in the health care institutions.
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objeCtives: Palivizumab prophylaxis against respiratory syncytial virus (RSV) 
is provided monthly during the RSV season. CARESS is a prospective registry of 
infants who received ≥ 1 dose of palivizumab across 32 Canadian sites during 7 
seasons. The objective is to determine factors associated with palivizumab com-
pliance. Methods: Neonatal and demographic data were collected at enrolment. 
Palivizumab utilization, compliance, and outcomes related to respiratory illness 
(RI) and RSV hospitalization were collected monthly. Compliance was defined 
as receipt of all expected injections at 25–35 day intervals during the RSV sea-
son. Results: A total of 13,310 infants were enrolled. Infants received 89.0% ± 
18.23% of their expected injections and 9745 (73.2%) were administered within 
appropriate inter-dose intervals.Compliant versus non-compliant infants had a 
rate of 9.2 RSV and 57.5 RI versus 11.7 RSV and 65.5 RI hospitalizations / 100-patient-
years respectively. Compliance differed between prophylaxis indications (χ 2= 24.6, 
p< 0.0005); with congenital heart disease the most non-compliant (CHD; n= 668, 
47.2%), followed by chronic lung disease (CLD; n= 470, 44.8%), prematurity (≤ 35 
weeks gestational age; n= 3643, 41.6%) and other medical disorders (n= 831, 39.6%). 
A greater proportion of non-compliant infants were Aboriginal (4.8% vs. 2.4%, 
χ 2= 57.8, p< 0.0005), attended daycare (4.0% vs. 3.3%, χ 2= 5.0, p= 0.03), had a mother 
who smoked (17.1% vs. 12.0%, χ 2= 69.0, p< 0.0005), and lived with ≥ 1 smoker (31.7% 
vs.26.1%, χ 2= 49.7, p< 0.0005). Significant factors independently associated with com-
pliance (OR, 95%CI) were: maternal education (1.38, 1.22–1.58), Aboriginal descent 
(0.57, 0.47–0.70), smoke exposure (0.70, 0.52–0.94), CLD (0.74, 0.56–0.99), maternal 
smoking (0.79, 0.68–1.01), daycare (0.82, 0.68–0.99), and indication for prophylaxis. 
Compliance by both expected number of injections and inter-dose intervals was 
associated with lower hazard rates of RI hospitalization (HR= 0.86, 95%CI= 0.74-0.99, 
p= 0.04). ConClusions: Higher maternal education and lower RI hospitalization 
was associated with full compliance where as non-compliance was associated with 
other demographic factors and differed by palivizumab indication.
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objeCtives: The economic burden of asthma on the UK National Health Service 
(NHS) is the largest amongst allergic diseases, costing approximately £800 million 
per year. Current Global Initiative for Asthma guidelines recommend adding a long 
acting β 2-agonist (LABA) to a low-dose inhaled corticosteroid (ICS) in patients who 
are on ICS monotherapy and have uncontrolled asthma. The fixed-dose combina-
tion of fluticasone propionate and salmeterol (FLUT/SAL), available in a pressurized 
metered dose inhaler (pMDI) device, is the most commonly prescribed ICS/LABA 
combination. A new fixed-dose combination of fluticasone propionate and formo-
terol fumarate (FLUT/FORM) in pMDI is now available. In a 12 week non-inferiority 
study, FLUT/FORM demonstrated comparable efficacy to FLUT/SAL. This study esti-
mates the budget impact of using FLUT/FORM as an alternative to FLUT/SAL for 
an average NHS clinical commissioning group (CCG) within England. Methods: 
Current pMDI prescribing data were taken from a real-world UK patient database 
(Cegedim Strategic Data). Annual costs to the NHS for drug acquisition, administra-
tion, and monitoring were estimated for FLUT/FORM and FLUT/SAL. Annual cost 
data were used to estimate the potential budget impact for the use of FLUT/FORM 
versus FLUT/SAL, based on an estimated average population size for a CCG (260,000 
persons or 0.41% of the UK population). Results: Assuming similar levels of ICS 
use with both combination regimens, annual drug acquisition costs per person were 
lower with FLUT/FORM (£411.58) than with FLUT/SAL (£509.06). The difference in 
acquisition costs and otherwise comparable input costs between the treatments, 
results in potential annual savings of £61,952.14 for an average CCG, assuming 
uptake of FLUT/FORM over FLUT/SAL in 50% of existing patients. ConClusions: 
The comparable efficacy and lower acquisition costs for FLUT/FORM compared 
to FLUT/SAL make it a cost-saving option, from a NHS England CCG perspective, 
for the treatment of asthma patients requiring combination maintenance therapy 
using a pMDI.
PRS13
Budget imPact analySiS of SteP-down StRategy veRSuS 
conventional theRaPy in the tReatment of noSocomial Pneumonia 
cauSed By gRam PoSitive BacteRia in mexico
Peniche-Otero G.1, Herrera-Rojas J.1, Gryzbowski E.1, Baeza-Cruz G.1, Huicochea-Bartelt J.L.2, 
Muciño-Ortega E.2
1Customized Premium Products S.A. de C.V., Mexico City, Mexico, 2Pfizer S.A. de C.V., Ciudad de 
México, Mexico
objeCtives: Previous reports of national literature estimated 15,135 cases of noso-
comial pneumonia caused by Gram-positive bacteria (GPB) in Mexico, of which 
approximately 51% (95%CI 43%-59%) are candidates to use the step-down strategy 
